Dihydropyridine calcium channel blockers vs placebo
- Time course for blood pressure lowering of dihydropyridine calcium channel blockers 2014 · Cochrane Headline outcomes onlyno estimate extracted16 studies · 2768 participantsModerate
Lower blood pressure targets showed no clear difference in total mortality compared with standard blood pressure targets (moderate certainty).
Lower blood pressure targets showed no clear difference in total serious adverse events compared with standard blood pressure targets (low certainty).
Lower blood pressure targets showed no clear difference in total cardiovascular events compared with standard blood pressure targets (low certainty).
Lower blood pressure targets showed no clear difference in cardiovascular mortality compared with standard blood pressure targets (moderate certainty).
It is very uncertain whether lower blood pressure targets changes participant withdrawals due to adverse effects compared with standard blood pressure targets (very low certainty).
The intervention showed no clear difference in overall mortality (low certainty).
It is very uncertain whether the intervention changes cardiovascular events (very low certainty).
It is very uncertain whether the intervention changes proportion of subjects with SBP < 140 mmHg and DBP < 90 mmHg (very low certainty).
Beta‐blockers showed no clear difference in total mortality compared with placebo (moderate certainty).
Beta‐blockers showed no clear difference in withdrawal due to adverse effect compared with diuretics (low certainty).
Beta‐blockers showed no clear difference in total mortality compared with calcium‐channel blockers (moderate certainty).
Beta‐blockers probably leads to higher total cardiovascular disease compared with calcium‐channel blockers (moderate certainty).
Beta‐blockers probably leads to higher total stroke compared with calcium‐channel blockers (moderate certainty).
Beta‐blockers showed no clear difference in total coronary heart disease compared with calcium‐channel blockers (moderate certainty).
Beta‐blockers showed no clear difference in withdrawal due to adverse effect compared with calcium‐channel blockers (low certainty).
Beta‐blockers may leads to lower total cardiovascular disease compared with placebo (low certainty).